https://heartresearch.holy-cross.com---https://heartresearch.holy-cross.com/studies-list
Skip to Content
image description
  • image description
  • image description
  • image description

Studies List

Anticoagulation

ANNEXA-4

Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who have Acute Major Bleeding.

Principal Investigator: Rishi Anand, MD

Contact: 954-229-8400 

Harmony.bourque@holy-cross.com

Atrial Fibrillation

ELITE (CV185-161)

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients.

Principal Investigator: Karan Munuswamy, MD

Contact: 954-229-8400

Christine.Lepurage@holy-cross.com

Atrial Fibrillation

(BOAT-AF)

BenchmarkinganOralAnticoagulantTreatmentRateinNonvalvularAtrial Fibrillation:AStudy ofClinicalCharacteristicswithInsightfromPatientand Physician Perspectives

Principal Investigator: Joshua Larned, MD

Contact: 954-229-8400

Harmony.bourque@holy-cross.com

Atrial Fibrillation

RIVAROXAFL 4002

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.

Principal Investigator: Ricky Schneider, MD

Contact: 954-346-0864

Sanchez.grey@holy-cross.com

Cardiology and Diabetes

HARMONY Outcomes Trial (GLP116174)

A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus.

Principal Investigator: Ricky Schneider, MD

Contact: 954-346-0864

Sanchez.grey@holy-cross.com

 

Heart Failure

Pioneer HF (LCZ696)

A multicenter, randomized, double-blind, double dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril and valsartan (LCZ696} versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of lCZ696 compared to enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF).

Principal Investigator: Joshua Larned, MD

Contact: 954-229-8400

Christine.Lepurage@holy-cross.com



Heart Failure

Panache (17582)

A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetics and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure and preserved ejection fraction

Principal Investigator: Joshua Larned, MD

Contact: 954-229-8400

Christine.Lepurage@holy-cross.com

Heart Failure

VICTORIA HF (MK-1242-001)

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction.

Principal Investigator: Joshua Larned, MD

Contact: 954-229-8400

Harmony.bourque@holy-cross.com

Heart Failure

Pantheon (15128)

A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction.

Principal Investigator: Joshua Larned, MD

Contact: 954-229-8400

Christine.Lepurage@holy-cross.com

Heart Failure

BeAT-HF


BAROSTIM NEO® – Baroreflex Activation Therapy® for Heart Failure.

Principal Investigator: Joshua Larned, MD

Contact: 954-229-8400

Harmony.bourque@holy-cross.com

Heart Failure

EMPEROR-Preserved (1245.110)

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).

Principal Investigator: Karan Munuswamy, MD

Contact: 954-229-8400

Christine.Lepurage@holy-cross.com

Heart Failure

PRIME HF

PredischaRge initiation of Ivabradine in ManagEment of Heart Failure.

Principal Investigator: Joshua Larned, MD

Contact: 954-229-8400

Christine.lepurage@holy-cross.com

Heart Failure

EMPEROR-Reduced (1245.121)

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).

Principal Investigator: Karan Munuswamy, MD

Contact: 954-229-8400

Christine.Lepurage@holy-cross.com

Humanitarian Use Device

HUD-Impella RP System

The intent of the therapy with the Impella RP System is to provide a percutaneous circulatory support system to restore normal right heart hemodynamics, reduce right ventricular work, and allow the right heart time to potentially recover adequate contractile function or to be bridged to the next therapy.

Principal Investigator: Irving David, MD

Contact: 954-229-8400

clinicaltrials@holy-cross.com

Humanitarian Use Devices

HUD-Wingspan

WingspanTM Stent System with GatewayTM PTA Balloon Catheter - The Wingspan Stent System and Gateway PTA Balloon Catheter is authorized by Federal law for use in improving cerebral artery lumen diameter in patients with intracranial atherosclerotic disease, refractory to medical therapy, in intracranial vessels with >50% stenosis that are accessible to the system.

Principal Investigator: Laszlo Miskolczi, MD
Contact: 954-229-8400
Fort Lauderdale, FL

Pages

Human Heart

Holy Cross Hospital is committed to cutting-edge heart research and to offering the most advanced cardiac care in South Florida. Meet our team of principal investigators who are dedicated to providing the best cardiac care in our community.

Request Info

Clinical Trial Info

Directions

image description

Studies

man getting heart procedure